Skip to main content
News Directory 3
  • Business
  • Entertainment
  • Health
  • News
  • Sports
  • Tech
  • World
Menu
  • Business
  • Entertainment
  • Health
  • News
  • Sports
  • Tech
  • World
Changes in dopamine markers found in 24 people with long COVID in Canada — ScienceAlert

Long COVID may involve loss of dopamine-releasing neurons, study says

October 4, 2026 Jennifer Chen Health
News Context
At a glance
  • Brain scans of 24 people with long COVID reveal signs of potential injury to dopamine-releasing neurons, according to a peer-reviewed study published in the journal eBioMedicine.
  • The study utilized positron emission tomography alongside a radioactive tracer to evaluate a specific marker of dopamine nerve endings in the brain.
  • Study author psychiatrist Jeffrey Meyer from the Brain Health Imaging Center in Canada suggested that dopamine-releasing neurons may be damaged or lost in some people suffering from long...
Original source: ua.news

Brain scans of 24 people with long COVID reveal signs of potential injury to dopamine-releasing neurons, according to a peer-reviewed study published in the journal eBioMedicine. Canadian researchers using positron emission tomography found a lower signal for a dopamine nerve-ending marker across several areas of the striatum in patients experiencing persistent, debilitating symptoms after clearing an initial SARS-CoV-2 infection. ScienceAlert reported that the signal reduction was associated with higher levels of apathy, cognitive complaints, poorer memory test results, and slower performance on motor and reading tasks.

PET Scans Reveal Dopamine Deficits in Patients

The study utilized positron emission tomography alongside a radioactive tracer to evaluate a specific marker of dopamine nerve endings in the brain. Researchers focused on the striatum, a structure involved in regulating motivation, movement speed, and memory. While none of the 24 participants had an active SARS-CoV-2 infection at the time of the scans, all reported lingering cognitive and physical impairment. As a group, they performed worse on memory and movement speed tests than healthy control participants of the same age. According to findings highlighted by UA.News, about 25 percent of the variation in individual symptoms among the participants could be associated with these altered dopaminergic nerve ending indicators.

Long COVID Involves Loss of Dopamine-Releasing Neurons

Study author psychiatrist Jeffrey Meyer from the Brain Health Imaging Center in Canada suggested that dopamine-releasing neurons may be damaged or lost in some people suffering from long COVID.

Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons.

Jeffrey Meyer

Meyer noted that this specific type of injury is well recognized for producing symptoms like lack of motivation and motor slowing in other neurological conditions. While previous research among people with long COVID has largely concentrated on brain inflammation and immune system changes, this study points directly toward functional disruption within the brain’s dopamine pathways. The authors proposed two theoretical mechanisms for the damage: either SARS-CoV-2 directly infects dopamine-producing neurons due to a high density of compatible receptors, or elevated markers for brain cells that prune back synapses cause damage to the circuits.

Long COVID Brain Scans Reveal Dopamine Damage

Preliminary Findings Require Larger Groups to Confirm Results

Because PET scanning measures a specific protein located at nerve endings rather than counting neuron density directly, the authors emphasized that their conclusions remain preliminary. The findings indicate an association between lower dopamine markers and specific symptoms, but the study does not establish a definitive causal relationship. Future investigations will require larger, controlled groups to confirm the robustness and generalizability of the results across wider populations. Although the study authors hypothesized that drugs affecting the dopamine system might eventually offer therapeutic value for certain patients, they cautioned that such medications can carry significant side effects. Study author Jeffrey Meyer has a patent application for a dopamine-related method of treating long COVID.

More on this story: New Alzheimer Drugs Lecanemab and Donanemab Slow Cognitive Decline

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Coach Jung Sung-sook criticized for lax management of judoka Jeong Su-jin
  • Sarah Morey runs Potters Arf in memory of Emily Lockley

Related

Search:

News Directory 3

News Directory 3 catalogs US newspapers, news services, newsstands and digital news outlets across all 50 states. Browse local publishers by city, state, or topic, and follow current headlines linked back to their original sources.

Quick Links

  • Disclaimer
  • Terms and Conditions
  • About Us
  • Advertising Policy
  • Contact Us
  • Cookie Policy
  • Editorial Guidelines
  • Privacy Policy

Browse by State

  • Alabama
  • Alaska
  • Arizona
  • Arkansas
  • California
  • Colorado

© 2026 News Directory 3. All rights reserved.
For contact, advertising, copyright, issues email: office@newsdirectory3.com